[go: up one dir, main page]

MX2016009063A - Preparacion farmaceutica que contiene compuesto de acido piridilaminoacetico. - Google Patents

Preparacion farmaceutica que contiene compuesto de acido piridilaminoacetico.

Info

Publication number
MX2016009063A
MX2016009063A MX2016009063A MX2016009063A MX2016009063A MX 2016009063 A MX2016009063 A MX 2016009063A MX 2016009063 A MX2016009063 A MX 2016009063A MX 2016009063 A MX2016009063 A MX 2016009063A MX 2016009063 A MX2016009063 A MX 2016009063A
Authority
MX
Mexico
Prior art keywords
pharmaceutical preparation
acid compound
preparation containing
pyridylaminoacetic acid
glaucoma
Prior art date
Application number
MX2016009063A
Other languages
English (en)
Other versions
MX370361B (es
Inventor
Kawabata Noriko
Shams Naveed
Andre Kroon Henk-
Kawata Hisashi
Original Assignee
Santen Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53520400&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2016009063(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Santen Pharmaceutical Co Ltd filed Critical Santen Pharmaceutical Co Ltd
Publication of MX2016009063A publication Critical patent/MX2016009063A/es
Publication of MX370361B publication Critical patent/MX370361B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Un objetivo de la presente invención es encontrar cual de un número enorme de compuestos de ácido piridilaminoacético tiene un efecto de disminución de presión intraocular particularmente excelente y se puede utilizar como un agente terapéutico o preventivo para glaucoma o hipertensión ocular o un agente de disminución de presión intraocular, y encontrar cómo el compuesto encontrado se utiliza y/o que dosis del compuesto se instila a un paciente (principalmente, un humano) para lograr un efecto terapéutico o preventivo efectivo. Se proporciona una preparación farmacéutica para tratamiento o prevención de glaucoma o hipertensión ocular, que comprende 0.0003 a 0.01% (p/v) de (6-{[4-(pirazol-1-il)bencil] (piridin-3-ilsulfonil)aminometil}piri din-2-ilamino) acetato de isopropilo o una sal del mismo.
MX2016009063A 2014-01-10 2015-01-08 Preparación farmacéutica que contiene compuesto de ácido piridilaminoacético. MX370361B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461925882P 2014-01-10 2014-01-10
PCT/JP2015/050366 WO2015105144A1 (ja) 2014-01-10 2015-01-08 ピリジルアミノ酢酸化合物を含む医薬製剤

Publications (2)

Publication Number Publication Date
MX2016009063A true MX2016009063A (es) 2016-09-28
MX370361B MX370361B (es) 2019-12-10

Family

ID=53520400

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016009063A MX370361B (es) 2014-01-10 2015-01-08 Preparación farmacéutica que contiene compuesto de ácido piridilaminoacético.

Country Status (26)

Country Link
US (9) US9415038B2 (es)
EP (3) EP3424503B1 (es)
JP (7) JP5846338B2 (es)
KR (1) KR101824829B1 (es)
CN (2) CN108743587B (es)
AU (1) AU2015205188B2 (es)
BR (1) BR112016015763B8 (es)
CA (1) CA2936026C (es)
CL (1) CL2016001756A1 (es)
DK (1) DK3093018T3 (es)
EA (1) EA031734B1 (es)
ES (2) ES2711091T3 (es)
GE (1) GEP20186917B (es)
HK (1) HK1223036A1 (es)
HU (1) HUE041653T2 (es)
IL (1) IL246447B (es)
MX (1) MX370361B (es)
MY (1) MY163235A (es)
PH (1) PH12016501357B1 (es)
PL (1) PL3093018T3 (es)
PT (1) PT3093018T (es)
SG (1) SG11201605653RA (es)
TR (1) TR201902019T4 (es)
TW (1) TWI598113B (es)
UA (1) UA117506C2 (es)
WO (1) WO2015105144A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3424503B1 (en) * 2014-01-10 2020-09-02 Santen Pharmaceutical Co., Ltd Pharmaceutical preparation including pyridylamino acetic acid compound
CA2934612C (en) * 2014-01-10 2021-09-07 Santen Pharmaceutical Co., Ltd. Pyridylaminoacetic acid compound and polyoxyethylene castor oil-containing pharmaceutical composition
BR112016015909B1 (pt) 2014-01-10 2020-09-29 Santen Pharmaceutical Co., Ltd. Composição farmacêutica contendo composto de ácido piridilaminoacético
JP5951922B1 (ja) * 2014-12-12 2016-07-13 興和株式会社 水性組成物
TWI755356B (zh) * 2015-07-01 2022-02-21 日商參天製藥股份有限公司 含檸檬酸酯之緩釋劑之用途
JP7032134B2 (ja) 2015-07-09 2022-03-08 参天製薬株式会社 ピリジルアミノ酢酸化合物を含有する予防及び／又は治療剤
WO2018230713A1 (ja) 2017-06-16 2018-12-20 学校法人同志社 カスパーゼ阻害活性を有する化合物、これらの化合物を含む、角膜内皮の症状、障害または疾患を治療または予防するための医薬およびその応用
CA3067332A1 (en) 2017-06-16 2018-12-20 The Doshisha Mtor-inhibitor-containing medicine for treating or preventing ophthalmic symptoms, disorders, or diseases, and application thereof
JP7250685B2 (ja) * 2017-09-29 2023-04-03 参天製薬株式会社 ピリジルアミノ酢酸化合物を含有する医薬
WO2019124487A1 (ja) 2017-12-21 2019-06-27 参天製薬株式会社 オミデネパグの組合せ
EP3733179A4 (en) 2017-12-28 2021-09-15 Santen Pharmaceutical Co., Ltd. PHARMACEUTICAL PREPARATION CONTAINING A PYRIDYLAMINOACETIC ACID COMPOUND
MX2020011301A (es) 2018-04-24 2021-01-29 Allergan Inc Uso de clorhidrato de pilocarpina para el tratamiento de afecciones oculares.

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002356420A (ja) * 2001-03-27 2002-12-13 Santen Pharmaceut Co Ltd 安定な水性液剤
US8648097B2 (en) 2008-03-12 2014-02-11 Ube Industries, Ltd. Pyridylaminoacetic acid compound
ES2564010T3 (es) * 2009-03-30 2016-03-17 Ube Industries, Ltd. Composición farmacéutica para tratar o prevenir el glaucoma
JP2011057633A (ja) 2009-09-11 2011-03-24 Ube Industries Ltd ピリジルアミノ酢酸化合物を含有する医薬
US20120202863A1 (en) * 2011-02-03 2012-08-09 Gerald Horn Compositions and methods for treatment of glaucoma
US9339496B2 (en) * 2012-07-13 2016-05-17 Santen Pharmaceutical Co., Ltd. Composition for treating or preventing glaucoma comprising a sulfonamide compound, and a beta-receptor antagonist
CA3099517C (en) * 2012-07-13 2022-04-26 Santen Pharmaceutical Co., Ltd. Combinations comprising a sulfonamide compound for the treatment of glaucoma or ocular hypertension
JP2014019650A (ja) * 2012-07-13 2014-02-03 Santen Pharmaceut Co Ltd スルホンアミド化合物とタフルプロストの組み合わせ
US20140018350A1 (en) 2012-07-13 2014-01-16 Asahi Glass Co., Ltd. Combination of sulfonamide compound and tafluprost
EP3424503B1 (en) * 2014-01-10 2020-09-02 Santen Pharmaceutical Co., Ltd Pharmaceutical preparation including pyridylamino acetic acid compound
CA2934612C (en) 2014-01-10 2021-09-07 Santen Pharmaceutical Co., Ltd. Pyridylaminoacetic acid compound and polyoxyethylene castor oil-containing pharmaceutical composition
BR112016015909B1 (pt) 2014-01-10 2020-09-29 Santen Pharmaceutical Co., Ltd. Composição farmacêutica contendo composto de ácido piridilaminoacético

Also Published As

Publication number Publication date
HK1223036A1 (zh) 2017-07-21
US12295946B2 (en) 2025-05-13
US20250235439A1 (en) 2025-07-24
ES2711091T3 (es) 2019-04-30
CA2936026A1 (en) 2015-07-16
EA031734B1 (ru) 2019-02-28
US20200289483A1 (en) 2020-09-17
US20240000763A1 (en) 2024-01-04
MY163235A (en) 2017-08-30
USRE48183E1 (en) 2020-09-01
US11197849B2 (en) 2021-12-14
PL3093018T3 (pl) 2019-05-31
NZ721620A (en) 2021-08-27
PH12016501357B1 (en) 2020-12-09
BR112016015763B8 (pt) 2020-09-15
US10702511B2 (en) 2020-07-07
CL2016001756A1 (es) 2017-05-12
US11793798B2 (en) 2023-10-24
TW201609186A (zh) 2016-03-16
ES2834334T3 (es) 2021-06-17
EP3750541A1 (en) 2020-12-16
CA2936026C (en) 2022-04-19
EP3424503B1 (en) 2020-09-02
CN108743587B (zh) 2021-04-30
JP2016027060A (ja) 2016-02-18
CN105899209A (zh) 2016-08-24
EA201691402A1 (ru) 2016-10-31
JP7726542B2 (ja) 2025-08-20
JP2024019479A (ja) 2024-02-09
BR112016015763B1 (pt) 2020-09-01
PT3093018T (pt) 2019-01-10
JPWO2015105144A1 (ja) 2017-03-23
WO2015105144A1 (ja) 2015-07-16
TR201902019T4 (tr) 2019-03-21
IL246447A0 (en) 2016-08-31
JP5846338B2 (ja) 2016-01-20
EP3093018A1 (en) 2016-11-16
US9415038B2 (en) 2016-08-16
US20190105310A1 (en) 2019-04-11
KR101824829B1 (ko) 2018-02-01
PH12016501357A1 (en) 2016-08-15
JP2019108363A (ja) 2019-07-04
TWI598113B (zh) 2017-09-11
AU2015205188B2 (en) 2019-11-14
GEP20186917B (en) 2018-11-12
US20220054466A1 (en) 2022-02-24
US20150196541A1 (en) 2015-07-16
CN105899209B (zh) 2018-09-11
JP7087040B2 (ja) 2022-06-20
HUE041653T2 (hu) 2019-05-28
AU2015205188A1 (en) 2016-07-14
SG11201605653RA (en) 2016-08-30
JP2025142352A (ja) 2025-09-30
JP2021006593A (ja) 2021-01-21
CN108743587A (zh) 2018-11-06
US10179127B2 (en) 2019-01-15
US20180169079A1 (en) 2018-06-21
KR20160101030A (ko) 2016-08-24
DK3093018T3 (en) 2019-02-04
JP6785330B2 (ja) 2020-11-18
US20160324838A1 (en) 2016-11-10
JP6491588B2 (ja) 2019-03-27
US9943510B2 (en) 2018-04-17
JP2022111280A (ja) 2022-07-29
MX370361B (es) 2019-12-10
JP7402922B2 (ja) 2023-12-21
EP3093018A4 (en) 2017-09-13
IL246447B (en) 2020-06-30
EP3424503A1 (en) 2019-01-09
EP3093018B1 (en) 2018-11-28
UA117506C2 (uk) 2018-08-10

Similar Documents

Publication Publication Date Title
MX2016009063A (es) Preparacion farmaceutica que contiene compuesto de acido piridilaminoacetico.
MX393855B (es) Terapia de combinación que comprende un inhibidor de raf y trametinib
MX2021011563A (es) Derivados de 2,3-dihidro-isoindol-1-ona, como inhibidores de la btk quinasa y composiciones farmaceuticas que los incluyen.
EA201691151A1 (ru) Соединения для лечения пациентов с ros1-мутантными раковыми клетками
TR201904455T4 (tr) Nükleer taşıma modülatörleri olarak 1,2,4-triazoller ve bunların kullanımları.
EA201691789A1 (ru) Фармацевтические композиции и соли 1,2,4-оксадиазолбензойной кислоты
WO2017022962A8 (ko) Ripk 억제제를 유효성분으로 포함하는 면역질환의 예방 또는 치료용 조성물
MX2015010829A (es) Compuestos terapeuticos y sus usos.
MX2020010300A (es) Sales monoacidas de 6-aminoisoquinolinas y usos de las mismas.
NZ721500A (en) Use of halogen compounds for the treatment and prevention of heart attack and ischemic injury
RU2018135973A (ru) Фармацевтическая комбинация, содержащая метроформин и дигидрокверценин, и ее применение для лечения рака
SG10201810404XA (en) Combination comprising a glucocorticoid and edo-s101
MX381440B (es) Composicion farmaceutica para tratar colitis ulcerativa.
PH12015501945B1 (en) Formulations of organic compounds
CO2019004004A2 (es) Composición farmacéutica y método para el tratamiento de la enfermedad del hígado graso no alcohólico
MX384072B (es) Compuesto derivado de pirrolo-piridina, metodo para preparar el mismo y composicion farmaceutica que contiene el mismo como ingrediente activo para la prevencion o el tratamiento de enfermedades relacionadas con la proteina cinasa.
CO7170176A2 (es) Nuevo compuesto que tiene la capacidad para inhibir la enzima deshidrogenasa11b-hidroxiesteroide tipo 1(11b-hsd1) o sal farmaceúticamente aceptable del mismo, método para producir el mismo, y composición farmaceútica que contiene el mismo como ingrediente activo
MX379253B (es) Formulaciones de oximetazolina estabilizadas y sus usos.
EA201690903A1 (ru) Лечение глаукомы с использованием лаквинимода
MX2015013115A (es) Nuevos regimenes de dosificacion de celgosivir para el tratamiento de dengue.
SG10201809673RA (en) Treatment of androgen deprivation therapy associated symptoms
AR101227A1 (es) Combinaciones de un derivado de n-tiazolil-4-fenoxibencenosulfonamida y un agente farmacéuticamente activo seleccionado a partir de gabapentina y pregabalina para tratar dolor
MX2018013474A (es) Acidos carboxilicos para aplicacion en la primera infancia.
NZ740722A (en) Oral suspension for treating eosinophilic esophagitis
IN2013MU02585A (es)

Legal Events

Date Code Title Description
FG Grant or registration